Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use

Thomas R Meinel¹, Philipp Bücke¹, Lucio D'Anna², Giovanni Merlino³, Diana Aguiar de Sousa^{4

5

6}, Sven Poli^{7

8}, Jan C Purrucker⁹, Davide Strambo¹⁰, Michele Romoli¹¹, Gian Marco De Marchis^{12

13}, Waltraud Pfeilschifter¹⁴, Marialuisa Zedde¹⁵, João Pedro Marto¹⁶, Paolo Candelaresi¹⁷, Robin Lemmens^{18

19}, Pasquale Scoppettuolo²⁰, Malin Woock²¹, Pawel Kermer²², Espen Saxhaug Kristoffersen²³, Malik Ghannam²⁴, Senta Frol²⁵, Christian H Nolte²⁶, Yusuke Yakushiji²⁷, Emmanuel Touzé²⁸, Timo Uphaus²⁹, Marina Mannino³⁰, George Ntaios³¹, Visnja Padjen³², Nils Henninger³³, Freschta Zipser-Mohammadzada¹, Marisa E Mariano^{4

5

6}, Carolina Guerreiro^{4

5

6}, Alessandra Burini³, Laura Ceccarelli³, Mariarosaria Valente³, Alexandra Gomez-Exposito^{7

8}, Antonia Kleeberg⁹, Guillaume Thevoz¹⁰, Patrik Michel¹⁰, Gianluca Stufano¹¹, Dimitrios Vlachos^{12

13}, Matthias Herrmann¹⁴, Bárbara Rodrigues¹⁶, Emanuele Spina¹⁷, Vincenzo Andreone¹⁷, Arne Allardt²¹, Qasem N Alshaer²⁴, Christoph Riegler²⁶, Takenobu Kunieda²⁷, Marion Boulanger²⁸, Marianne Hahn²⁹, Dimitra Papadimitriou³¹, Jayachandra Muppa³³, Louise Maes^{18

19}, Anna Ranta³⁴, Alicia Tyson³⁴, P Alan Barber³⁵, Alan Davis³⁶, Teddy Y Wu³⁷, Johannes Kaesmacher^{38

39

40}, Urs Fischer¹, David J Seiffge¹; International DO-IT Collaboration

Collaborators, Affiliations

Collaborators

Affiliations

¹ Department of Neurology, Stroke Research Center Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland. (T.R.M., P.B., F.Z.-M., U.F., D.J.S.).
² Division of Brain Sciences, Imperial College London, United Kingdom (L.D.).
³ Clinical Neurology and Stroke Unit, Department of Head, Neck and Neurosciences, Udine University Hospital, Italy (G.M., A.B., L.C., M.V.).
⁴ Stroke Centre, Lisbon Central University Hospital Center-ULS São José, Portugal (D.A.d.S., M.E.M., C.G.).
⁵ CEEM e Instituto de Anatomia, Faculdade de Medicina, Universidade de Lisboa, Portugal (D.A.d.S., M.E.M., C.G.).
⁶ Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal (D.A.d.S., M.E.M., C.G.).
⁷ Department of Neurology and Stroke, University of Tübingen, Germany. (S.P., A.G.-E.).
⁸ Hertie Institute for Clinical Brain Research, University of Tübingen, Germany. (S.P., A.G.-E.).
⁹ Department of Neurology, Heidelberg University Hospital, Germany (J.C.P., A.K.).
¹⁰ Stroke Center, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Switzerland (D.S., G.T., P.M.).
¹¹ Neurology and Stroke Unit, Department of Neurosciences, Bufalini Hospital, AUSL Romagna, Cesena, Italy (M.R., G.S.).
¹² Department of Neurology and Stroke Center, University Research and Teaching Hospital, Cantonal Hospital St. Gallen, Switzerland (G.M.D.M., D.V.).
¹³ Medical Faculty, University of Basel, Switzerland (G.M.D.M., D.V.).
¹⁴ Department of Neurology and Clinical Neurophysiology, Klinikum Lueneburg, Germany (W.P., M. Herrmann).
¹⁵ Neurology Unit, Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy (M.Z.).
¹⁶ Department of Neurology, Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Lisbon, Portugal (J.P.M., B.R.).
¹⁷ Neurology and Stroke Unit, A.O.R.N. Antonio Cardarelli, Napoli, Italy (P.C., E.S., V.A.).
¹⁸ Department of Neurosciences, Experimental Neurology, KU Leuven, Belgium (R.L., L.M.).
¹⁹ Department of Neurology, University Hospitals Leuven, Belgium (R.L., L.M.).
²⁰ Neurology Department, Cliniques Universitaires Saint Luc-UCL, Bruxelles, Belgique (P.S.).
²¹ Department of Neurology, Sahlgrenska University Hospital, Göteborg, Sweden (M.W., A.A.).
²² Department of Neurology, Nordwest-Krankenhaus Sanderbusch, Friesland Kliniken GmbH, Sande and University Medicine Göttingen, Germany (P.K.).
²³ Department of Neurology, Akershus University Hospital, Lørenskog, Norway (E.S.K.).
²⁴ Department of Neurology, University of Iowa Hospitals and Clinics (M.G., Q.N.A.).
²⁵ Department of Vascular Neurology, University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia (S.F.).
²⁶ Department of Neurology with Experimental Neurology and Center for Stroke Research, Charité-Universitätsmedizin Berlin, Germany (C.H.N., C.R.).
²⁷ Department of Neurology, Kansai Medical University, Osaka, Japan (Y.Y., T.K.).
²⁸ Department of Neurology, CHU de Caen Normandie, France (E.T., M.B.).
²⁹ Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany (T.U., M. Hahn).
³⁰ Department of Neurology and Stroke Unit, AOOR Villa Sofia-V. Cervello, Palermo, Italy (M.M.).
³¹ 1 Propaedeutic Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece (G.N., D.P.).
³² Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Serbia (V.P.).
³³ Department of Neurology, University of Massachusetts Chan Medical School, Worcester (N.H., J.M.).
³⁴ Department of Neurology, Wellington Hospital, New Zealand (A.R., A.T.).
³⁵ Department of Medicine, University of Auckland, New Zealand (P.A.B.).
³⁶ Department of Medicine, Whangarei Hospital, New Zealand (A.D.).
³⁷ Department of Neurology, Christchurch Hospital, New Zealand (T.Y.W.).
³⁸ University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Switzerland. (J.K.).
³⁹ Diagnostic and Interventional Neuroradiology, Tours, France (J.K.).
⁴⁰ Le Studium Loire Valley Institute for Advanced Studies, Orléans, France (J.K.).

PMID: 40693390
DOI: 10.1161/STROKEAHA.125.051384

Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use

Thomas R Meinel et al. Stroke. 2025.

. 2025 Jul 22.

doi: 10.1161/STROKEAHA.125.051384. Online ahead of print.

Authors

Collaborators

Affiliations

¹ Department of Neurology, Stroke Research Center Bern, Inselspital, Bern University Hospital, University of Bern, Switzerland. (T.R.M., P.B., F.Z.-M., U.F., D.J.S.).
² Division of Brain Sciences, Imperial College London, United Kingdom (L.D.).
³ Clinical Neurology and Stroke Unit, Department of Head, Neck and Neurosciences, Udine University Hospital, Italy (G.M., A.B., L.C., M.V.).
⁴ Stroke Centre, Lisbon Central University Hospital Center-ULS São José, Portugal (D.A.d.S., M.E.M., C.G.).
⁵ CEEM e Instituto de Anatomia, Faculdade de Medicina, Universidade de Lisboa, Portugal (D.A.d.S., M.E.M., C.G.).
⁶ Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal (D.A.d.S., M.E.M., C.G.).
⁷ Department of Neurology and Stroke, University of Tübingen, Germany. (S.P., A.G.-E.).
⁸ Hertie Institute for Clinical Brain Research, University of Tübingen, Germany. (S.P., A.G.-E.).
⁹ Department of Neurology, Heidelberg University Hospital, Germany (J.C.P., A.K.).
¹⁰ Stroke Center, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Switzerland (D.S., G.T., P.M.).
¹¹ Neurology and Stroke Unit, Department of Neurosciences, Bufalini Hospital, AUSL Romagna, Cesena, Italy (M.R., G.S.).
¹² Department of Neurology and Stroke Center, University Research and Teaching Hospital, Cantonal Hospital St. Gallen, Switzerland (G.M.D.M., D.V.).
¹³ Medical Faculty, University of Basel, Switzerland (G.M.D.M., D.V.).
¹⁴ Department of Neurology and Clinical Neurophysiology, Klinikum Lueneburg, Germany (W.P., M. Herrmann).
¹⁵ Neurology Unit, Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy (M.Z.).
¹⁶ Department of Neurology, Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Lisbon, Portugal (J.P.M., B.R.).
¹⁷ Neurology and Stroke Unit, A.O.R.N. Antonio Cardarelli, Napoli, Italy (P.C., E.S., V.A.).
¹⁸ Department of Neurosciences, Experimental Neurology, KU Leuven, Belgium (R.L., L.M.).
¹⁹ Department of Neurology, University Hospitals Leuven, Belgium (R.L., L.M.).
²⁰ Neurology Department, Cliniques Universitaires Saint Luc-UCL, Bruxelles, Belgique (P.S.).
²¹ Department of Neurology, Sahlgrenska University Hospital, Göteborg, Sweden (M.W., A.A.).
²² Department of Neurology, Nordwest-Krankenhaus Sanderbusch, Friesland Kliniken GmbH, Sande and University Medicine Göttingen, Germany (P.K.).
²³ Department of Neurology, Akershus University Hospital, Lørenskog, Norway (E.S.K.).
²⁴ Department of Neurology, University of Iowa Hospitals and Clinics (M.G., Q.N.A.).
²⁵ Department of Vascular Neurology, University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia (S.F.).
²⁶ Department of Neurology with Experimental Neurology and Center for Stroke Research, Charité-Universitätsmedizin Berlin, Germany (C.H.N., C.R.).
²⁷ Department of Neurology, Kansai Medical University, Osaka, Japan (Y.Y., T.K.).
²⁸ Department of Neurology, CHU de Caen Normandie, France (E.T., M.B.).
²⁹ Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany (T.U., M. Hahn).
³⁰ Department of Neurology and Stroke Unit, AOOR Villa Sofia-V. Cervello, Palermo, Italy (M.M.).
³¹ 1 Propaedeutic Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece (G.N., D.P.).
³² Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Serbia (V.P.).
³³ Department of Neurology, University of Massachusetts Chan Medical School, Worcester (N.H., J.M.).
³⁴ Department of Neurology, Wellington Hospital, New Zealand (A.R., A.T.).
³⁵ Department of Medicine, University of Auckland, New Zealand (P.A.B.).
³⁶ Department of Medicine, Whangarei Hospital, New Zealand (A.D.).
³⁷ Department of Neurology, Christchurch Hospital, New Zealand (T.Y.W.).
³⁸ University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Switzerland. (J.K.).
³⁹ Diagnostic and Interventional Neuroradiology, Tours, France (J.K.).
⁴⁰ Le Studium Loire Valley Institute for Advanced Studies, Orléans, France (J.K.).

PMID: 40693390
DOI: 10.1161/STROKEAHA.125.051384

Abstract

Background: Intravenous thrombolysis (IVT) in patients with recent ingestion of direct oral anticoagulants (DOACs) is a frequent challenge and remains controversial. The benefit of DOAC reversal before IVT is uncertain.

Methods: Using target trial methodology, we analyzed data from 28 comprehensive stroke centers. Patients on DOACs were included if they met IVT criteria, had a National Institutes of Health Stroke Scale score of ≥2, and last DOAC intake within 48 hours or was undeterminable. Safety and efficacy outcomes (symptomatic intracerebral hemorrhage, any intracerebral hemorrhage, major bleeding, 90-day mortality, and good functional outcome [modified Rankin Scale score of 0-2 or return to baseline]) were compared between those receiving IVT versus no IVT and IVT with versus without reversal. In addition, a comparison was made with patients from the New Zealand stroke registry, all of whom underwent reversal with idarucizumab. We adjusted for covariates known to be associated with safety and efficacy outcomes, including age, stroke severity, intended thrombectomy, blood glucose, blood pressure, DOAC reversal, and time from last intake.

Results: Overall, 1342 patients fulfilled the target trial criteria. The median age was 80 (interquartile range, 73-86) years, median National Institutes of Health Stroke Scale score was 11, 50% were female, and 52% of patients received endovascular therapy. IVT was given in 342 of 1342 (25%) patients. Of these, 141 (41.2%) had verified DOAC intake <12 hours before admission, and 92 (26.9%) within 12 to 24 hours. Symptomatic intracerebral hemorrhage occurred in 10 of 328 (3.0%) of patients receiving IVT and 54 of 921 (5.9%) patients not receiving IVT (adjusted difference, -2.1% [95% CI, -5.3% to +1.2]). Patients receiving IVT were more likely to have good functional outcomes (adjusted difference, +14.4% [95% CI, +7.1% to +21.8%]). Comparing 289 patients with reversal (from the additional New Zealand registry) and 283 patients without reversal before IVT (from the target trial population), there was no significant difference in symptomatic intracerebral hemorrhage, major bleeding, or efficacy outcomes.

Conclusions: This target trial confirms previous observational data regarding the safety of off-label IVT in patients with recent DOAC intake. More data and dedicated trials are needed for patients with confirmed high DOAC plasma levels and regarding the efficacy and safety of DOAC reversal before IVT.

Keywords: anticoagulants; atrial fibrillation; stroke; therapeutic thrombolysis.

PubMed Disclaimer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use

Collaborators

Affiliations

Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use

Authors

Collaborators

Affiliations

Abstract

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous